#USA #San Francisco #Allelica #PROACT 3 #CAD Testing

Allelica's Impact on Cardiovascular Health through Polygenic Risk Scores

Allelica, renowned for its innovation in multi-ancestry clinical polygenic risk score (PRS) testing, is stepping into the spotlight as a key collaborator in the PROACT 3 clinical trial. This pivotal research is being conducted at Mass General Brigham, featuring a distinguished team led by Dr. Akl Fahed from Massachusetts General Hospital and Harvard Medical School.

The main objective of the PROACT 3 trial is to explore how the disclosure of coronary artery disease (CAD) polygenic risk scores can influence critical health indicators such as LDL cholesterol levels, cardiovascular health, and the engagement of individuals with their healthcare providers. Dr. Giordano Botta, the CEO and Co-Founder of Allelica, emphasized the company's pride in supporting this research, noting its alignment with Allelica's mission to enhance patient care through advanced diagnostics.

Understanding Polygenic Risk Scores and Their Clinical Utility

Polygenic risk scores serve as a valuable tool in predicting the likelihood of developing certain conditions based on genetic information. In the context of cardiovascular diseases, they offer insights that are crucial for early intervention, especially among populations that traditional screening methods may overlook. The PROACT 3 trial represents a significant step in validating the clinical utility of CAD PRS testing, further amplifying the potential for these scores to inform preventive healthcare strategies.

PROACT 3 is designed as a randomized trial involving 500 adults who currently show no signs of cardiovascular disease and are not undergoing LDL cholesterol-lowering treatments. Participants are recruited through the primary care network of Mass General Brigham and are set to receive Allelica's multi-ancestry CAD PRS.

The trial's unique design will provide two cohorts: one receiving immediate disclosure of their genetic risk and the other informed after a 12-month period. This approach aims to assess the real-world implications of disclosing genetic risk scores on participants’ behavior and health outcomes over the course of a year.

Building on Prior Research

The PROACT 3 endeavor builds on the foundation established by the previously funded NIH trials, PROACT 1 and PROACT 2, which focused on the detection and treatment of subclinical coronary atherosclerosis influenced by high genetic risk. While those prior studies examined the broader implications of polygenic risk, PROACT 3 hones in on the personal impact of risk disclosure, specifically within a large healthcare system context.

It addresses essential questions within the realm of preventive genomics: Does informing patients about their genetic risk lead to measurable improvements in crucial cardiovascular measures and health-related behaviors? Through the outcomes gathered from the trial, direct insights into the effectiveness of PRS in motivating individuals towards proactive health management are anticipated.

Innovation at the Forefront of Healthcare

Allelica's technology, recognized in Nature Communications in late 2023, enables healthcare providers across the United States to utilize a polygenic risk score that is accurate across diverse populations. As research continues to unveil the relationship between genetics and cardiovascular health, Allelica aims to ensure that its testing not only identifies individuals at heightened genetic risk but also allows healthcare systems to tailor early interventions more effectively.

By offering personalized risk stratification, Allelica serves to empower patients with vital knowledge about their health status, thus enhancing their engagement with healthcare services. The advancements stemming from the PROACT 3 trial and similar initiatives underscore the pivotal role that precision medicine and genomics will play in the future of healthcare, potentially reshaping how conditions like coronary artery disease are managed.

In conclusion, Allelica's involvement in the PROACT 3 clinical trial signifies a forward leap in understanding genetic risk and its implications for heart health. As the study progresses, it holds the promise not just of advancing research, but of forging pathways that could ultimately lead to life-saving interventions for those identified through polygenic risk assessments.